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We conducted a genome-wide association study of essential tremor, a common movement disorder characterized mainly by a
postural and kinetic tremor of the upper extremities. Twin and family history studies show a high heritability for essential tremor.
The molecular genetic determinants of essential tremor are unknown. We included 2807 patients and 6441 controls of European
descent in our two-stage genome-wide association study. The 59 most signiﬁcantly disease-associated markers of the discovery
stage were genotyped in the replication stage. After Bonferroni correction two markers, one (rs10937625) located in the serine/
threonine kinase STK32B and one (rs17590046) in the transcriptional coactivator PPARGC1A were associated with essential
tremor. Three markers (rs12764057, rs10822974, rs7903491) in the cell-adhesion molecule CTNNA3 were signiﬁcant in the
combined analysis of both stages. The expression of STK32B was increased in the cerebellar cortex of patients and expression
quantitative trait loci database mining showed association between the protective minor allele of rs10937625 and reduced ex-
pression in cerebellar cortex. We found no expression differences related to disease status or marker genotype for the other two
genes. Replication of two lead single nucleotide polymorphisms of previous small genome-wide association studies (rs3794087 in
SLC1A2, rs9652490 in LINGO1) did not conﬁrm the association with essential tremor.
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Introduction
Essential tremor, deﬁned as a ‘bilateral, largely symmetric
postural or kinetic tremor’ (Deuschl et al., 1998), is a
common movement disorder with a reported prevalence of
0.9%, increasing to 4.6% in the population above the age of
65 (Louis and Ferreira, 2010). The disease is progressive and
signiﬁcant disabilities occur (Lorenz et al., 2011; Louis et al.,
2011). Hands and arms are predominantly affected but
head, voice and leg tremor occur. Twin studies estimated
the heritable component of essential tremor between 45%
and 90% (Kuhlenba¨umer et al., 2014). Two small genome-
wide association studies (GWAS) (452/436 cases per
discovery stage) identiﬁed essential tremor associated single
nucleotide polymorphisms (SNPs) in SLC1A2 (Thier et al.,
2012), coding for the glutamate transporter EAAT2, and in
LINGO1 (Stefansson et al., 2009), involved in oligodendro-
cyte differentiation and axonal regeneration. Replication stu-
dies yielded mixed results for both genes.
Materials and methods
Patient recruitment
Approval was obtained from all responsible ethics committees.
All participants gave written consent. Movement disorder
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specialists at each recruitment site (Supplementary material)
based the diagnosis mainly on presence of postural and
action tremor in the arms exceeding the amplitude seen in
enhanced physiological tremor and not attributable to other
causes (Parkinson’s disease, dystonia, medication).
Supplementary Table 1 lists the sample characteristics of the
discovery and replication samples. Controls were ethnically
matched to cases and either derived from biobanks PopGen
(Krawczak et al., 2006) and KORA-gen (Wichmann et al.,
2005) (Europe sites) or from North American sites. All pa-
tients and controls were of North-Western European (CEU)
ancestry. Four hundred and thirty-six samples from Kiel,
Tu¨bingen and Innsbruck from the discovery stage of a previ-
ous GWAS of essential tremor (Thier et al., 2012) were geno-
typed anew.
Genotyping
All samples were processed on Axiom Genome-Wide CEU 1
Array Plate by Affymetrix. Genotypes were called using the
Affymetrix Power Tools (APT, version 1.15.1). Genotypes of
case and control samples were called together in ﬁve batches.
Quality control
Quality control was performed at sample and marker level
using pyGenClean (version 1.2.3) (Lemieux Perreault et al.,
2013). Samples were excluded if the missingness rate exceeded
2% or sex information was discordant. We controlled all sam-
ples for deviating ethnicity (based on the ethnic classiﬁcation
of 1000 genome samples from CEU, YRI and JPT-CHB popu-
lations) and cryptic relatedness [identity by descent
(IBD)4 0.125]. Markers failing the following thresholds: miss-
ingness rate (52%), minor allele frequency rate (45%) or
Hardy Weinberg Equilibrium (P4 0.0001) were excluded.
We examined markers for informative missingness and batch
effects (Anderson et al., 2010). We report detailed procedures
and numbers of excluded samples for individual quality con-
trol steps in Supplementary Table 2.
Imputation
The pruned dataset was pre-phased using SHAPEIT (version
2.12). We used IMPUTE2 (version 2.3.0) for imputation. In
both steps 1000 Genomes Phase I integrated variant set release
(v3) in NCBI b37 was used as reference panel. Only imputed
variants with a minor allele frequency4 0.01 and an imput-
ation quality score (INFO) above 0.3 were analysed further.
Tests for association
We used (i) a logistic additive model implemented in PLINK
(version 1.07) (Purcell et al., 2007); and (ii) GEMMA’s linear
mixed model (version 0.94) (Zhou and Stephens, 2012) for
association testing. We adjusted for sex and population strati-
ﬁcation using 10 dimensions of an IBD-derived multidimen-
sional scaling matrix (PLINK) or using a GEMMA-generated
relatedness matrix. The imputed dosage data were analysed
using GEMMA.
Replication
The most promising SNPs (n = 59) in the ﬁnding stage were
studied further. We selected SNPs in narrow regional bins in
linkage disequilibrium (LD) and controlled their cluster plots.
LD bins were deﬁned as SNPs being located in a 500 kb
window and with r240.5. We used two Sequenom panels,
processed all samples in one centre and tested for association
using logistic models implemented in PLINK. Due to incom-
plete phenotype data, additional covariates could not be
included without severely compromising sample size. We inves-
tigated follow-up SNPs in the combined discovery and replica-
tion data using logistic regression (PLINK).
Genotyping of variants associated
with essential tremor in previous
genome-wide association studies
We genotyped all available samples using TaqMan probes for
SNPs rs9652490 in LINGO1 and rs3794087 in SLC1A2 and
called alleles using QuantStudioTM Real-Time PCR software
v1.1 (Life Technologies).
Clinicopathological assessment of
patients and tissue handling
Ethics review board approval and participants’ written con-
sents were obtained. All patient brain samples are from indi-
viduals diagnosed with deﬁnite essential tremor (Deuschl et al.,
1998). Control individuals were reported to be free of neuro-
logical disorders. Autopsy procedures have been described pre-
viously (Rajput et al., 2004). One hemisphere of all patient
brains was examined histologically in detail by a neuropath-
ologist. Controls underwent a standard neuropathological as-
sessment. Nineteen cases with essential tremor and ﬁve control
subjects were of Canadian origin, 12 control subjects were of
German origin (Supplementary Table 3).
DNA/RNA extraction
We isolated total RNA from 30mg lateral cerebellar cortex
tissue from 19 essential tremor cases and 17 control subjects
using AllPrep DNA/RNA Mini Kit (Qiagen). RNA concen-
tration was measured using NanoDrop Spectrophotometer
and RNA quality determined by gel electrophoresis.
Quantitative reverse transcription
polymerase chain reaction
We prepared cDNA from 500ng RNA for quantitative PCR
(qPCR) using the RevertAid H Minus Reverse Transcriptase
kit (Thermo Fisher). RNA expression was analysed for the
genes PPARGC1A, STK32B, CTNNA3, ACTB and the
Purkinje cell housekeeping gene PCP2. Expression analysis
was performed using a StepOnePlus system and SYBR
Green PCR Master Mix (Thermo Fisher). We performed at
least two technical replicates in one qPCR run (four replicates
in two qPCR runs for ACTB, PCP2 and STK32B). We calcu-
lated expression using bioconductor packages ReadqPCR and
NormqPCR. Technical replicates were averaged, then gene-
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expression was normalized using ACTB and PCP2 and expres-
sion differences assessed using Student’s t-test.
Results
Discovery stage
All discovery samples were genotyped under identical con-
ditions. In the discovery stage 1778 patients with essential
tremor and 5376 control samples were genotyped and
416462 SNPs included after quality pruning. The estimated
statistical power was 90% for an odds ratio (OR) of 1.3
(Supplementary Fig. 1). We ﬁrst computed marker-wise
P-values using the logistic additive model implemented in
PLINK. QQ-plots showed a high level of genomic inﬂation
( = 1.25) despite including 10 dimensions of an IBD-
derived multidimensional scaling matrix, indicating incom-
plete correction for population stratiﬁcation. Therefore, we
also used GEMMA’s linear mixed model with adjustment
for sex and population stratiﬁcation, which reduced the
genomic inﬂation to a very low level with  = 1.01 (Zhou
and Stephens, 2012). In addition, we analysed the imputed
dosage data using GEMMA (Manhattan and QQ-Plots:
Supplementary Figs 2–4).
Two variants successfully replicated in
independent cohort
In the replication stage we genotyped an independent
cohort of 1029 patients with essential tremor and 1065
control samples for 59 best markers selected from all
three analyses (PLINK, GEMMA, GEMMA imputed
data). We applied logistic regression analysis (PLINK) in
the replication stage and in a combined analysis of both
stages. Two variants, both selected from the GEMMA ﬁrst
stage analysis, met a Bonferroni-corrected signiﬁcance
threshold of P = 8.47  104 (Tables 1 and 2). The ﬁrst
variant rs10937625 [P = 7.36  104, OR = 0.77, 95%
conﬁdence interval (CI) 0.66–0.90] locates to an intronic
region of STK32B (Fig. 1A), coding for a serine/threonine
kinase. The second variant rs17590046 [P = 6.81  104,
OR = 0.75 (95% CI 0.64–0.89)] lies in an intron of
PPARGC1A (Fig. 1B), a transcriptional coactivator. LD
analysis showed no additional associated markers in neigh-
bouring genes (Fig. 1A and B). None of the SNPs chosen
based on the PLINK analysis of the discovery stage or the
imputed data was successfully replicated. Therefore, we do
not report any imputed data. Combined analysis of ﬁrst
and second stage data revealed a region on chromosome
10q21.3 containing variants with small P-values in PLINK
as well as GEMMA analysis, including three intronic vari-
ants in the adhesion molecule gene CTNNA3 [rs7903491,
P = 2.49  107, OR = 1.10 (95% CI 1.03–1.18);
rs12764057, P = 1.19  108, OR = 1.17 (95% CI 1.09–
1.26) and rs10822974, 1.65  107, OR = 1.16 (95% CI
1.08–1.24)] (Fig. 1C). The variants are located close to T
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each other but are not in strong LD (r250.8) and testing
for independent haplotypic effects using PLINK showed no
correlation (Fig. 1C). Association results for individual
stages and combined analysis of the 20 most signiﬁcant
markers are summarized in Supplementary Table 4. The
minor allele frequencies of successfully replicated markers
rs10937652 and rs1750046 were highly consistent between
different recruiting centres and discovery/replication sam-
ples while higher deviations between stages were observed
for markers in CTNNA3 (Supplementary Table 5 and
Supplementary Fig. 5). Heterogeneity metrics of associated
markers between different stages and recruitment sites are
displayed in Table 1 and forest plots in Supplementary Figs
6–10. In many studies, including this one, the age at onset
data follow a bimodal distribution (Supplementary Fig. 11).
Stratiﬁcation into early (525 years) and late (450 years)
age at onset groups did not reveal large differences in the
allele frequencies of the top 20 markers between both
groups (Supplementary Table 6 and Supplementary Fig.
12). We do not present subgroup analyses because these
did not provide additional insights.
No replication of previously
reported associations
We genotyped SNPs rs3794087 in the SLC1A2 gene and
rs9652490 in LINGO1, which were associated with essen-
tial tremor in previous GWAS in all available samples
(2847 cases/1977 controls) (Supplementary material).
Controls provided by Kora and PopGen could not be
included because we could not obtain DNA for these sam-
ples. Neither of the two SNPs nor neighbouring SNPs
showed a signiﬁcant association with essential tremor
(Supplementary Table 7, Supplementary Figs 13 and 14).
The STK32B SNP rs10937625 is
located in a regulatory region
Variant annotation using HaploReg3 revealed that
rs10937625 is located in a DNase hypersensitive region
but did not provide further information for the other es-
sential tremor-associated SNPs. A BioGRID search did not
ﬁnd any evidence for interactions or shared GO Processes
between the genes STK32B, PPARGC1A and CTNNA3.
Increased expression of STK32B in
brains of patients with
essential tremor
We examined the expression of STK32B, PPARGC1A and
CTNNA3 in lateral cerebellar cortex of 19 patients with
essential tremor and 17 control subjects by reverse tran-
scription (RT)-qPCR. Age at death, post-mortem intervals,
and sex did not signiﬁcantly differ between patients and
controls. The expression of STK32B was signiﬁcantly
increased in essential tremor brains compared to control
brains (P = 0.026) (Supplementary Table 8 and
Supplementary Fig. 15). The expression difference was
not associated with genotype at rs10937625
(Supplementary Table 9 and Supplementary Fig. 16). A
linear regression model identiﬁed disease status as the
only determinant of STK32B expression (Supplementary
Fig. 15). We found no genotype or phenotype related dif-
ferences in the expression of PPARGC1A or CTNNA3.
STK32B marker rs10937625 asso-
ciated with eQTL in public database
In the Braineac eQTL database, the expression of probeset
2716778 (Affymetrix Probeset ID, chr4:5532972-5533090)
located in the STK32B coding region is highly associated
with the genotype of SNP rs1093762 (P5 0.0008) in cere-
bellar cortex but not in other brain regions (Trabzuni et al.,
2011) (Supplementary Fig. 18). We observed an additive,
negative effect of the minor, protective allele on expression
of the STK32B probe set. Expression of PPARGC1A and
CTNNA3 were not associated with the genotypes of the
corresponding essential tremor-associated SNPs in the
Braineac data.
Discussion
Standard analysis of our discovery stage data using PLINK
suggested a high level of population stratiﬁcation.
Table 2 Genotype counts and minor allele frequencies for the three associated loci
Genotype counts cases Genotype counts controls
SNP CHR BP Minor
Allele (a)
Major
Allele (A)
aa aA AA MAF aa aA AA MAF
rs10937625 4 5 128 159 C T 113 942 1622 0.2182 403 2492 3410 0.2615
rs17590046 4 24 362 541 C T 68 775 1888 0.1668 263 2112 4047 0.2054
rs12764057 10 68 845 715 G T 485 1283 930 0.4175 898 2974 2537 0.3721
rs10822974 10 68 850 419 G A 625 1271 637 0.4976 1827 3116 1312 0.5412
rs7903491 10 68 917 164 A G 453 1311 881 0.4191 1347 3208 1848 0.4609
MAF = minor allele frequency; SNP = dbSNP ID of the marker; CHR = chromosome; BP = chromosomal position (GRCh37).
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GEMMA’s relatedness matrix is known to be particularly
suited for the correction of population stratiﬁcation. The
very low mean 2 metric of 1.0048 in the GEMMA ana-
lysis made us suspect signiﬁcant levels of overcorrection
and loss of power. To minimize type 1 errors (PLINK) as
well as type 2 errors (GEMMA) we selected the top SNPs
from all analysis types for replication. Only the third and
fourth ranked SNPs in the GEMMA analysis of the discov-
ery stage (rs10937625, rs17590046) were signiﬁcantly
associated with essential tremor in the replication stage.
We choose to report three additional SNPs in the
CTNNA3 gene, which were among the top variants in
the discovery sample in both the PLINK as well as the
GEMMA analysis. However, it has to be noted that these
SNPs failed replication and carry an increased risk of a type
1 error.
The biological function of the serine/threonine kinase
STK32B is unknown. The gene is located in a 520 kb de-
letion causing the rare skeletal dysplasia Ellis-Van-Creveld
syndrome (Temtamy et al., 2008). The association of
rs10937625 in the STK32B gene with essential tremor,
the increased expression in the cerebellar cortex of patients
with essential tremor and the association of the protective
minor allele with reduced STK32B expression in cerebellar
cortex in the Braineac eQTL database support a role of
STK32B in the pathogenesis of essential tremor. We
found no association between the rs10937625 genotype
and STK32B expression in our samples which might be a
related to the small sample size.
The other essential tremor-associated SNP, rs17590046 is
located in the PPARGC1A gene encoding the peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1a). PGC-1a is a transcriptional coactivator of genes
involved in energy metabolism and mitochondrial function
(Wu et al., 1999). Genetic and functional studies suggest a
role in the pathogenesis of various neurodegenerative dis-
orders (Weydt et al., 2006). We found no evidence that
rs17590045 is related to the expression of PPARGC1A.
The CTNNA3 gene, harbouring the SNPs rs7903491,
rs12764057, rs10822974 codes for catenin alpha 3, a
cell–cell adhesion molecule genetically linked to
Alzheimer’s disease (Miyashita et al., 2007).
We are fully aware that the most severe limitations of our
study are the lack of genome-wide signiﬁcance of the repli-
cated markers in the discovery stage and incomplete har-
monization of clinical data throughout our cases. The lack
of genome-wide signiﬁcance in the GEMMA analysis of the
Figure 1 Fine mapping of 500 kb windows centred around
each of the three essential tremor-associated loci. Top to
bottom: Chromosome ideogram followed by genes (horizontal line)
Figure 1 Continued
and their coding regions (vertical bars), negative logarithmic P-values
of all markers for the discovery stage (left y-axis) against chromo-
somal position (x-axis) and recombination rates for the genomic
positions (right y-axis) in pink. Bottom: Heatmap indicating LD.
Saturated red indicating high LD, white indicating no LD.
(A) STK32B; (B) PPARGC1A; and (C) CTNNA3.
3168 | BRAIN 2016: 139; 3163–3169 S. H. Mu¨ller et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/139/12/3163/2433570 by Institute of C
hild H
ealth/U
niversity C
ollege London user on 13 D
ecem
ber 2018
ﬁrst stage might be due to overcorrection in the GEMMA
based analysis. Therefore, we would like to strongly en-
courage replication to conﬁrm or refute the hypotheses
provided by our study. Nevertheless, we would also like
to emphasize that this is by far the largest GWAS in essen-
tial tremor and we are conﬁdent that it will be the driving
force for the next generation of genetics and molecular
studies to come.
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